Full-Time

Quality Manager

Posted on 4/15/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

No salary listed

Expert

Mumbai, Maharashtra, India

Domestic travel as required up to approximately 20%

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • Minimum 10 years’ experience in Pharmaceutical Company in quality function
  • Experience in managing GxP supplier audits, internal audits, regulatory authority inspections
  • Ability to work independently and identify compliance risks and escalate when necessary
  • Strong sense of urgency
  • Ability to manage complex projects and timelines in a fast environment
  • Demonstrated interpersonal skills including strong negotiation skills
  • Excellent teamwork and coordination skills
  • Excellent verbal and writing skills and fluent in English and as applicable, local language is desired
Responsibilities
  • Management of quality operations to ensure its compliance with local regulatory authority and Takeda’s global requirements for importation, local testing, product release, repackaging, storage and distribution of Takeda products
  • Develop, implement and maintain a systematic, effective and efficient local Quality Management System (QMS) as per local regulatory authority and Takeda’s global requirements
  • Ensure all relevant Quality support are provided for all relevant post market activities for Takeda India and are executed timely as per local regulatory authority and Takeda’s global requirements
  • Initiate Quality Incident Notification to Management / escalation report for notifiable events in accordance with Takeda Global Procedure
  • Execute local recall/market action once the decision is endorsed by Market Action Committee (MAC) and ensure timely completion of the required actions
  • Support in establishing and maintaining local risk register
  • Responsible to ensure local Quality Council is conducted on a regular basis
  • Support Establish and lead internal audit and lead self-assessment program at the LOC
  • Lead the quality oversight of GxP supplier management, customer and distributor qualification and lifecycle management
  • Secondary point of contact to manage relationship, relevant communication and inspection with local regulatory authority on GWP, GDP and Controlled Substances matters
  • Delegated quality operations to ensure compliance to Clinical Quality Assurance for local clinical operations
  • As Quality Business Partner with local stakeholders, ensure quality support to local business projects and product launches are successful delivered in adherence to quality and regulatory compliance
  • Drive and strengthen the Quality Culture at the LOC
  • Provide support to other countries’ quality operations if needed

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.